CULLINAN THERAPEUTICS, INC. Total Shareholder Rtn Amt
CULLINAN THERAPEUTICS, INC. (CGEM) reported Total Shareholder Rtn Amt of $98.1 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-28.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-04-28
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $98.10 DEF 14A · filed 2026-04-28 |
| 2024-12-31 | $115.45 DEF 14A · filed 2026-04-28 |
| 2023-12-31 | $96.59K DEF 14A · filed 2026-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |